New strategies to improve tumor cell vaccine therapy

Jian Qiao, Haidong Dong

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The advantage of using a tumor cell vaccine is that it is rich in multiple tumor-associated antigens. The immune responses to those antigens are elicited by most of current tumor cell vaccines that are transduced with immunostimulatory cytokines or costimulatory molecules. However, the lack of long-lasting and objective tumor regression in clinical trials prompted reevaluation of the immunogenicity of tumor cell vaccines and the molecular basis of the immune responses they induced. New vectors for the genetic modification of tumor cell vaccines to improve immunogenicity have been developed. The identification of negative regulators during vaccination has lead to the discovery of new reagents to specifically target regulatory cells or molecules to improve the efficacy of these vaccines. On the basis of their enhancing effects during the cross-priming of CD8 T cells, toll-like receptor ligands have been used in the modification of tumor cells to improve their immunogenicity. Therefore, the endeavors in developing new tumor cell vaccines not only extend our knowledge about the tumor-reactive immunity but also promise an effective treatment regimen in human cancers.

Original languageEnglish (US)
Title of host publicationTargeted Cancer Immune Therapy
PublisherSpringer New York
Pages117-131
Number of pages15
ISBN (Print)9781441901699
DOIs
StatePublished - Dec 1 2009

Fingerprint

Active Immunotherapy
Cancer Vaccines
Cell- and Tissue-Based Therapy
Tumors
Vaccines
Cells
Neoplasms
Cross-Priming
Genetic Vectors
Toll-Like Receptors
Neoplasm Antigens
Antigens
Synthetic Vaccines
Molecules
T-cells
Immunity
Vaccination
Clinical Trials
Cytokines
Ligands

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Qiao, J., & Dong, H. (2009). New strategies to improve tumor cell vaccine therapy. In Targeted Cancer Immune Therapy (pp. 117-131). Springer New York. https://doi.org/10.1007/978-1-4419-0170-5_7

New strategies to improve tumor cell vaccine therapy. / Qiao, Jian; Dong, Haidong.

Targeted Cancer Immune Therapy. Springer New York, 2009. p. 117-131.

Research output: Chapter in Book/Report/Conference proceedingChapter

Qiao, J & Dong, H 2009, New strategies to improve tumor cell vaccine therapy. in Targeted Cancer Immune Therapy. Springer New York, pp. 117-131. https://doi.org/10.1007/978-1-4419-0170-5_7
Qiao J, Dong H. New strategies to improve tumor cell vaccine therapy. In Targeted Cancer Immune Therapy. Springer New York. 2009. p. 117-131 https://doi.org/10.1007/978-1-4419-0170-5_7
Qiao, Jian ; Dong, Haidong. / New strategies to improve tumor cell vaccine therapy. Targeted Cancer Immune Therapy. Springer New York, 2009. pp. 117-131
@inbook{093221a35f8747e8ada556f357215991,
title = "New strategies to improve tumor cell vaccine therapy",
abstract = "The advantage of using a tumor cell vaccine is that it is rich in multiple tumor-associated antigens. The immune responses to those antigens are elicited by most of current tumor cell vaccines that are transduced with immunostimulatory cytokines or costimulatory molecules. However, the lack of long-lasting and objective tumor regression in clinical trials prompted reevaluation of the immunogenicity of tumor cell vaccines and the molecular basis of the immune responses they induced. New vectors for the genetic modification of tumor cell vaccines to improve immunogenicity have been developed. The identification of negative regulators during vaccination has lead to the discovery of new reagents to specifically target regulatory cells or molecules to improve the efficacy of these vaccines. On the basis of their enhancing effects during the cross-priming of CD8 T cells, toll-like receptor ligands have been used in the modification of tumor cells to improve their immunogenicity. Therefore, the endeavors in developing new tumor cell vaccines not only extend our knowledge about the tumor-reactive immunity but also promise an effective treatment regimen in human cancers.",
author = "Jian Qiao and Haidong Dong",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/978-1-4419-0170-5_7",
language = "English (US)",
isbn = "9781441901699",
pages = "117--131",
booktitle = "Targeted Cancer Immune Therapy",
publisher = "Springer New York",

}

TY - CHAP

T1 - New strategies to improve tumor cell vaccine therapy

AU - Qiao, Jian

AU - Dong, Haidong

PY - 2009/12/1

Y1 - 2009/12/1

N2 - The advantage of using a tumor cell vaccine is that it is rich in multiple tumor-associated antigens. The immune responses to those antigens are elicited by most of current tumor cell vaccines that are transduced with immunostimulatory cytokines or costimulatory molecules. However, the lack of long-lasting and objective tumor regression in clinical trials prompted reevaluation of the immunogenicity of tumor cell vaccines and the molecular basis of the immune responses they induced. New vectors for the genetic modification of tumor cell vaccines to improve immunogenicity have been developed. The identification of negative regulators during vaccination has lead to the discovery of new reagents to specifically target regulatory cells or molecules to improve the efficacy of these vaccines. On the basis of their enhancing effects during the cross-priming of CD8 T cells, toll-like receptor ligands have been used in the modification of tumor cells to improve their immunogenicity. Therefore, the endeavors in developing new tumor cell vaccines not only extend our knowledge about the tumor-reactive immunity but also promise an effective treatment regimen in human cancers.

AB - The advantage of using a tumor cell vaccine is that it is rich in multiple tumor-associated antigens. The immune responses to those antigens are elicited by most of current tumor cell vaccines that are transduced with immunostimulatory cytokines or costimulatory molecules. However, the lack of long-lasting and objective tumor regression in clinical trials prompted reevaluation of the immunogenicity of tumor cell vaccines and the molecular basis of the immune responses they induced. New vectors for the genetic modification of tumor cell vaccines to improve immunogenicity have been developed. The identification of negative regulators during vaccination has lead to the discovery of new reagents to specifically target regulatory cells or molecules to improve the efficacy of these vaccines. On the basis of their enhancing effects during the cross-priming of CD8 T cells, toll-like receptor ligands have been used in the modification of tumor cells to improve their immunogenicity. Therefore, the endeavors in developing new tumor cell vaccines not only extend our knowledge about the tumor-reactive immunity but also promise an effective treatment regimen in human cancers.

UR - http://www.scopus.com/inward/record.url?scp=84900878307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900878307&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0170-5_7

DO - 10.1007/978-1-4419-0170-5_7

M3 - Chapter

AN - SCOPUS:84900878307

SN - 9781441901699

SP - 117

EP - 131

BT - Targeted Cancer Immune Therapy

PB - Springer New York

ER -